APTA Share Price Performance
UK£0.0095
0.01 (331.82%)
Price UK£0.0095
Share PriceUK£0.0095
Aptamer Group PLC Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
APTA Community Narratives
There are no narratives available yet.
Recent APTA News & Updates
Aptamer Group PLC Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.00084
- Gross Margin
- 52.92%
- Net Profit Margin
- -186.26%
- Debt/Equity Ratio
- 0.5%
Aptamer Group PLC Competitors
Snowflake Analysis
About APTA
- Founded
- 2008
- Employees
- 28
- CEO
- WebsiteView website
Aptamer Group PLC, together with its subsidiaries, provides binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally. The company offers Optimer, a platform that enables the discovery and development of optimized DNA and RNA aptamers; and Optimer +, a platform that discovers and develops of hybrid DNA-protein molecules that combines the features of Optimer and antibodies. It serves bioprocessing and diagnostic institutes, as well as pharmaceutical scientists. The company has strategic partnership with Unilever for the development of Optimer for use in deodorant, Neuro-Bio to develop reagents for Alzheimer’s disease test, and other pharma partner and AztraZeneca for drug delivery vehicle for fibrotic liver. Aptamer Group PLC has a development agreement with Invizius for the development of therapeutic. The company was founded in 2008 and is headquartered in York, the United Kingdom.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.K. Market Performance
- 7 Days: 1.2%
- 3 Months: 6.8%
- 1 Year: 14.6%
- Year to Date: 14.3%
The market has climbed 1.2% in the last 7 days, lead by the Healthcare sector with a gain of 9.0%. In the last year, the market has climbed 15%. As for the next few years, earnings are expected to grow by 14% per annum. Market details ›